Check for updates

OPEN ACCESS

EDITED BY Miguel Alfedo Castellan, University of Miami, United States

REVIEWED BY Bashir Ahmed Qureshi, Sindh Institute of Urology and Transplantation, Pakistan Sadaf Aba Umer Kodwavwala, Sindh Institute of Urology and Transplantation, Pakistan

*CORRESPONDENCE Zhang Zhao Michael__zhao@163.com

RECEIVED 01 November 2022 ACCEPTED 17 April 2023 PUBLISHED 02 May 2023

CITATION

Yuan Y, Liang Y-n, Li K-f, Ho Y-r, Wu Q-l and Zhao Z (2023) A meta-analysis: retrograde intrarenal surgery vs. percutaneous nephrolithotomy in children. Front. Pediatr. 11:1086345. doi: 10.3389/fped.2023.1086345

COPYRIGHT

© 2023 Yuan, Liang, Li, Ho, Wu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A meta-analysis: retrograde intrarenal surgery vs. percutaneous nephrolithotomy in children

Yi Yuan¹, Yan-nei Liang¹, Kai-feng Li¹, Yi-ru Ho¹, Qian-long Wu¹ and Zhang Zhao^{2*}

¹Department of Pediatric Urology Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China, ²Department of Urology Surgery, Guangzhou Women and Children's Medical Center of Guangzhou Medical University, Guangzhou, China

Backgrounds: The increasing prevalence of pediatric kidney stones worldwide makes minimally invasive lithotripsy like retrograde intrarenal surgery (RIRS) and percutaneous Nephrolithotomy (PCNL) more prevalent. However, their safety and efficacy are controversial. Consequently, a meta-analysis of the comparison between RIRS and PCNL is conducted.

Methods: Clinical trials were selected from PubMed, EMBASE, Scopus, and Cochrane Library databases. The data extraction and study quality assessment were performed by two individuals independently. The data relating to therapeutic effects were extracted and analyzed by Review manager 5.4.

Results: Thirteen studies involving 1,019 patients were included. The micro-PCNL excelled in stone-free rate (P = 0.003), postoperative fever rate (P = 0.02), and Clavien–Dindo II complications (P = 0.05). Notably, the mean age of the micro-PCNL group was younger than other groups (P = 0.0005). The operation time in mini-PCNL was longer than RIRS (P < 0.00001) but with high heterogeneity ($I^2 = 99\%$). There was no difference in Clavien–Dindo I, II, and III complications between the PCNL and the RIRS, but mini-PCNL showed a higher probability than RIRS in Clavien–Dindo I (P = 0.0008) and II complications (P = 0.007).

Conclusions: Compared with RIRS, micro-PCNL could be a better therapeutic option for kidney stones in children. Of note, more parameters should be analyzed to illustrate the efficacy of different minimally invasive surgeries for pediatric kidney stones due to poor cases in our study.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ #recordDetails, PROSPERO CRD42022323611

KEYWORDS

nephrolithotomy, percutaneous, retrograde intrarenal surgery, child, kidney calculi, meta-analysis

Abbreviations

CT, computerized tomography; EQ, efficiency quotient; PCNL, percutaneous nephrolithotomy; RIRS, retrograde intrarenal surgery; SWL, extracorporeal shockwave lithotrips; UTI, urinary tract infection; DJS, double-J stent; DJS w, double-J stent withdrawal; BMI, body mass index; CDC, centers for disease control and prevention; CR, complication rate; FURS, flexible ureteroscope; HU, hounsfeld unit; IQR, interquartile range; mPCNL, mini-percutaneous nephrolithotomy; SFR, stone-free rate; UAS, ureteral access sheath; USG, ultrasonography; IPA, infundibulopelvic angle; NSF, not stone free; HU, hounsfield units; IPA, infundibulopelvic angle; SPSS, statistical package for social sciences.

1. Introduction

Previous epidemiological studies have shown that the kidney stone incidence rate has risen. Besides, we found that pediatric patients were at high risk for kidney stone disease. Meanwhile, the risk of kidney stones in younger children was related to diabetes mellitus and hypertension. Simultaneously, the little girls likely suffered from kidney stone disease (1, 2).

RIRS (Retrograde Intrarenal Surgery, RIRS) is one of the primary measures to dispose of kidney stone disease in children. Compared with PCNL, RIRS has the advantage that it uses a natural orifice, which t requires no additional pathway for lithotripsies. For a child who suffers from kidney stones, RIRS can be a good option as the entrance of RIRS surgery is a natural pipeline of the human body which is smaller, the treatment is safer, and RIRS is more conducive to postoperative recovery (3). Nevertheless, during the operation of the RIRS for kids, the usage of sizeable medical instruments and the lowquality optics technology raise the possibility of the development of ureter ischemia, ureter injury, ureter stenosis, and reflux from the bladder and ureter (3).

PCNL is a frequently-used therapeutic option for pediatric kidney calculi. There are various types of PCNL, including standard PCNL (24–30 Fr), mini-PCNL (16–18/20 Fr), ultra-mini PCNL (11–14 Fr), micro-PCNL (<10 Fr), etc. PCNL is suitable for more giant stones. If we select using the Mini-Micro PCNL, the instrument can enter the renal cortex under the condition of direct vision. Besides, the expansion can be avoided after entering the renal cortex. Consequently, the operative time can be shortened, the radiation exposure can be decreased, and the complications, including hemorrhage and perforation, which were connected with expanding of the urinary tract, can be averted (4, 5).

Recently, many meta-analyses have compared the RIRS and PCNL's advantages and drawbacks (40, 41). However, we find that most of these articles are not convincing enough because the clinical trials included do not enough. Therefore, we aim to conduct a meta-analysis and systematic review of published articles to illustrate the superiority of RIRS and PCNL in treating children with upper urinary stones disease. We hope to include a more significant number of relevant articles and eliminate heterogeneity. We hope our meta-analysis could provide preferable guidance for surgeons treating children kidney stones.

2. Materials and methods

2.1. Information sources

Three investigators searched the databases independently, including PubMed, Scopus, Cochrane library, and Embase, with MeSH terms and Entry terms, to single out the eligible articles based on the inclusion and exclusion standards by May 30, 2022. The MeSH words include "child," "Nephrolithotomy", and "Percutaneous." Nevertheless, a part of the free term which had not to correspond with Mesh terms, including "Nephrolithotomy, "F-URS," "URS," "FURS," "flexible URS," Percutaneous," "Retrograde intrarenal surgery," "RIRS. "The comprehensive searching formula which we used in the PUBMED was the following: [retrograde flexible ureterorenoscopy(Title/Abstract)] OR [flexible ureterorenoscopy(Title/Abstract)] OR [F-URS(Title/ Abstract)] OR [URS(Title/Abstract)] OR [FURS(Title/Abstract)] OR [Retrograde intrarenal surgery(Title/Abstract)] OR [RIRS(Title/ Abstract)] OR [flexible URS(Title/Abstract)] OR [URS(Title/ Abstract)] AND [Nephrolithotomy, Percutaneous(MeSH Terms)] [Nephrolithotomies, Percutaneous(Title/Abstract)] OR OR [Percutaneous Nephrolithotomies(Title/Abstract)] OR [Percutaneous Nephrolithotomy(Title/Abstract)] OR [PCNL(Title/Abstract] AND [Child(MeSH Terms)] OR [Children(Title/Abstract)] OR [Paediatric (Title/Abstract)] OR [Pediatrics(Title/Abstract)].

2.2. Inclusion standard and exclusion standard

Inclusion standards:

- (1) The research included randomized controlled trials (RCTs) and retrospective clinical trials conducted in any country;
- (2) Patients: The kids (mean age below 12 year) who suffered from kidney stone diseases;
- (3) Intervening measure and comparing measure: There were at least two groups in the randomized controlled trials. The PCNL had been used in one, and RIRS had been used in another;
- (4) Outcome measurement: Only if the study included at least one of the following, including stone-free rate, operative time, BMI, blood transfusion, and overall complications, we would incorporate it into the meta-analysis;
- (5) The written language in English only;
- Exclusion standards:
- (1) Children with chronic renal failure and a history of renal calculi surgery.
- (2) We will eliminate the non-controlled trials;
- (3) The conference abstract, guidelines, case reports, not comparisons, review articles, and irrelevant interventions will be eliminated;

2.3. Data extraction

Two investigators independently conducted the data extraction procedure. The relevant information, characteristics, and results were retrieved and arranged into tables in Microsoft Excel 2019. The following data have been taken out:

- Stones' situation: stone size, stone location, stone density, stone masses, stone side, stone burden, stone site, stone composition, the opacity of the stones,
- (2) Operation condition: operation time, lithotripsy time, fluoroscopy time, tract dilation, Double-J stent, balloon dilation of the ureteral orifice, ureteral access sheaths,

imaging, irrigation fluid volume, the number of anesthesia sessions, frequency of fragmentation, laser, power, preoperative positive urine culture.

- (3) Postoperative outcome: stone-free rates, complication rates, the number of complications, and their Clavien grade (postoperative fever, sepsis, postoperative hematuria, renal colic, intraoperative bleeding, hydronephrosis, urinary tract infection, urosepsis.
- (4) Other variables: country, age, gender, BMI, SWL history, preoperative fever.

A third-party investigator will assess the study findings and, following sufficient deliberation, decide on an overall policy if there are differences in the data or between the findings of the two investigators.

2.4. Missing data

If the data recorded in the clinical trials were incomplete or led to high heterogeneity, we would conduct a sensitivity analysis, and the data were eliminated or not depending on the sensitivity analysis's result. When there were no precise sample sizes, we tried our best to estimate the sample sizes accurately. When dispersion degree in the continuous data was not reported with standard deviation (SD), but the *P*-values between two groups were presented, then these continuous data were included in our meta-analysis after the mathematical transition (6).

2.5. Quality assessment

Two researchers used the Cochrane handbook and the Jadad scale to evaluate the articles' quality. Furthermore, the Cochrane risk tool will assess all aspects of the risk, including selection bias, reporting bias, attrition bias, and performance bias. Besides, the assessment of the risk of bias was utilized by Review Manager V.5.4. Meanwhile, we will appraise the methodological quality of each trial and grade by using the Jadad scale. Finally, under the evaluation, if the studies can be obtained, 4 points or more will be identified as high-quality trials.

2.6. Data synthesis

After utilizing the Review Manager V.5.4 to analyze the inclusion trial's data, we got the mean difference (MD) for 95% CI and obtained the mean and SD from the continuous results. Also, the odds ratio (OR), which was obtained from the dichotomous data, is calculated for 95% CI. All of the data have been inspected by the random effects model. The forest plots revealed the heterogeneity of all statistical tests through the I^2 value. Furthermore, it is generally considered that 1%–25%: the heterogeneity is low; 25%–50%: moderate heterogeneity; >75%: significant heterogeneity (6). To specify the efficacy of the results, sensitivity analysis, and subgroup analysis were utilized. To evaluate the risk of publication bias, we used Egger's test.

Meanwhile, the *P*-value <0.05 demonstrates a statistically significant distinction between the RIRS group and the PCNL group. Ultimately, this meta-analysis was conducted under the Preferred Reporting Items for Systematic Reviews, and our study was evaluated with Meta-Analyses AMSTAR guidelines.

3. Results

3.1. Study selection

Four hundred and forty-seven studies were collected in total, which came from PubMed (n = 143), Embase (n = 129), Cochrane Library (n = 105), Scopus (n = 70), and additional records identified through other sources (n = 0). After removing duplicate studies, two hundred and thirty-three researches were retained. One hundred and thirty-nine articles were excluded based on their title/abstract, including twenty case reports, twenty-three irrelevant interventions, fourteen studies without comparisons, thirty-one NRCTs, and fifty-one review articles. Additionally, seventy-nine studies were rejected because twenty-three of them had irrelevant interventions, twenty-two of them were not randomized controlled trials, and thirty-four of them were review articles. Ultimately, 13 studies were selected in our final analysis by conducting qualitative synthesis on retained articles (Figure 1) (7–19).

3.2. Study characteristics

Thirteen studies were selected with 1,019 patients in total. Five hundred thirty children were treated with retrograde intrarenal surgery (RIRS group), while 489 children were conducted with percutaneous Nephrolithotomy (PCNL group). The trial data were from 2008 to 2021 in Asia, Europe, and Africa. The mean age of the trial population ranged from 1.6 to 10.9 years, and the sex ratio (male/female) ranged from 19/26 to 57/16. Meanwhile, the average operation time for kidney stones ranged from 18.5 min to 90 min, and the fluoroscopy time ranged from 4 s to 115 s. In addition, the ratio of kidney stone location (left/right) varies from 10/12 to 9/12. Moreover, the PCNL group used different specifications of mini-PCNL technology, and more than half of the RIRS group used 7.5 Fr F-URS. The main characteristics of each study are summarized in detail in **Tables 1, 2** below.

3.3. Quality assessment

Based on the Cochrane Risk of Bias tool, one study was at low risk, three studies were assessed as unclear risk, and two articles were at high risk of selection bias. Of the risks of performance bias, 12 tests were low-risk, but only one clause was considered to have ambiguous risk. At the same time, the risk of detection bias was low for nine tests and uncertain for the rest. Of the attrition bias, nine articles were considered low risk, one was



TABLE 1 Basic characteristics of included studies.

Trials	Year	Country	Time Range	PCNL	RIRS	Sai	size	
						Total	RIRS	PCNL
Bas (7)	2016	Asia-Turkey	August 2011–June 2015	Mini-PCNL	Flex-X2	81	36	45
Dogan (8)	2020	Asia-Turkey	June 2016–January 2020	Micro-PCNL	URF-P6 or URF-P7, Olympus	64	25	39
Ersoz (9)	2021	Europe-UK	2011–2018	15 Fr Mini-PCNL; 4.85 Fr Micro-PCNL; 24 Fr PCNL	7.5 Fr f-URS	76	45	31
Gamal (10)	2016	Africa-Egypt	June 2011–June 2014	Sheathless 19 Fr Mini-PCNL with 20 Fr amplatz sheath	7.5 Fr fibrooptic f-URS	42	21	21
Halinski (11)	2021	Europe-Poland	June 2015-August 2016	4.8 Fr Micro-PCNL	7.5 Fr f-URS	53	38	15
Jia (12)	2020	Asia-China	April 2016–July 2019	4.5-6.5 Fr Micro-PCNL	URF-P6, Olympus	61	25	36
Jones (13)	2020	Europe-UK	January 2010–December 2019	Mini-PCNL	Flex-X2	95	55	40
Pelit (14)	2016	Asia-Turkey	May 2013–January 2016	17 Fr Mini-PCNL	7.5 Fr f-URS	77	32	45
Resorlu (15)	2012	Asia-Turkey	January 2008–November 2011	11, 15.9, 17, and 22 Fr Mini-PCNL	_	201	95	106
Saad (16)	2015	Africa-Egypt	May 2011-February 2014	17 Fr Mini-PCNL	Flex-X2	43	21	22
Sen (17)	2017	Asia-Turkey	January 2015–April 2016	Micro-PCNL	URF-P6, Olympus	48	23	25
Wang (18)	2020	Asia-China	January 2015 and April 2016	Micro-PCNL	_	57	30	27
Zhang (19)	2021	Asia-China	June 2014–October 2019	Mini-PCNL	8-Fr/30 cm-42 cm	113	73	40

Trials	Year	Mean ag	ge (Year)	Gend	er (RIRS)	Ge (P	ender CNL)	Operat (mir	ion time nutes)	Fluoroso (seo	copy time cond)	Stone si	ze (mm)
		RIRS	PCNL	Male	Female	Male	Female	RIRS	PCNL	RIRS	PCNL	RIRS	PCNL
Bas (7)	2016	8.39 ± 4.72	5.62 ± 4.5	—	—	_	—	—	_	—	—	12.8 ± 3.03	13.97 ± 3.46
Dogan (8)	2020	6 ± 3.63	3.08 ± 3.29	14	11	25	14	60 ± 21.25	90 ± 30	15 ± 33.75	30 ± 56.25	7 ± 0.75	11 ± 3.5
Ersoz (9)	2021	8.1 ± 5.3	8.09 ± 5.5	19	26	19	12	47.6 ± 17.6	89.9 ± 54.1	_	115 ± 95	16.01 ± 7.4	20.1 ± 10.4
Gamal (10)	2016	9.2 ± 2.5	9.2 ± 2.5	—	_	_	_	41.0 ± 8	18.5 ± 9	_	_	_	—
Halinski (11)	2021	9.6 ± 3.78	8.2 ± 3.36	_	_	_	_	_	_	_	_	12.2 ± 0	13.5 ± 0
Jia (12)	2020	4.3 ± 2.5	4.5 ± 2.7	15	10	26	10	76.3 ± 32.4	53.9 ± 22.2	_	_	14 ± 2.8	14.18 ± 3
Jones (13)	2020	9.2 ± 3.5	8.8 ± 2.13	29	26	25	15	_	_	_	_	11.4 ± 10.25	14.5 ± 3.5
Pelit (14)	2016	3.65 ± 1.95	3.71 ± 1.89	17	15	24	21	46.25 ± 9.3	85.22 ± 12.87	4.15 ± 1.98	60.88 ± 23.38	19.3 ± 4.2	21.06 ± 5.6
Resorlu (15)	2012	9.3 ± 5.2	9.6 ± 1.9	53	42	56	50	42.1 ± 15.3	76.3 ± 21.2	33.2 ± 1.46	113.7 ± 36.6	14.3 ± 3.8	23.7 ± 44.2
Saad (16)	2015	6.44 ± 4.84	6.93 ± 3.55	14	7	14	8	79.5 ± 29.4	69.8 ± 29.6	96 ± 48	186 ± 66	_	_
Sen (17)	2017	10.9 ± 3	4 ± 2.3	_	_	_	_	62.3 ± 15.3	75.1 ± 18.9	39.9 ± 15.3	115 ± 35.4	13.7 ± 3.5	12.2 ± 2.8
Wang (18)	2020	1.75 ± 0.65	1.6 ± 0.83	_	_	_	_	23 ± 5	21 ± 4	_	_	17 ± 2	16 ± 3
Zhang (19)	2021	3 ± 0.675	3.2 ± 0.55	57	16	26	14	25 ± 2.5	40 ± 10	_	_	_	_

TABLE 2 Clinical characteristics of included studies.

considered high risk, and the remaining risks were unclear. In addition, 12 articles were assessed as low-risk in the reporting bias, one was considered high-risk, and other biases are unclear. In all the trials, the risks of performance bias, detection bias, attrition bias, and reporting bias were low, while the risks of other biases were high (Supplementary Figure S1).

Each item on the Jaded scale has a score of approximately 1–5, and a trial with a score of 3 or above is identified as a high-quality trial. According to our meta-analysis, five trials received a high-quality evaluation score of 3 or above, and five studies received a low-quality evaluation score of 2 (Supplementary Table S1).

3.4. Primary outcome

3.4.1. Analysis of the stone-free rate

Thirteen studies mentioned the stone-free rate included 1,087 patients. According to the analysis, there was a meaningful difference between the PCNL group and RIRS group [OR = 0.59; 95% CI (0.41, 0.84); P = 0.003] with moderate heterogeneity ($I^2 = 21\%$). When thirteen studies were grouped according to the use of mini-PCNL or micro-PCNL, heterogeneity decreased in both groups but to different degrees. There was a meaningful difference between the RIRS group and the micro-PCNL group [OR = 0.50; 95% CI (0.29, 0.88); P = 0.02], indicating slight heterogeneity ($I^2 = 8\%$). Additionally, the subgroup using mini-PCNL was not detected an overt difference between the RIRS and mini-PCNL groups [OR = 0.65; 95% CI (0.41, 1.03); P = 0.07], with moderate heterogeneity ($I^2 = 21\%$). The publication is unbiased, which was assessed by Egger's test.

3.4.2. Analysis of the characteristic data *3.4.2.1. Analysis of age*

Thirteen studies mentioned the age included 1,087 patients. According to the analysis, there was no difference between the PCNL group and RIRS group [MD = 0.06; 95% CI (-0.12, 0.24); P = 0.50] with high heterogeneity ($I^2 = 87\%$). There was a significant difference between the RIRS group and the micro-

PCNL group [MD = 0.62; 95% CI (0.27, 0.96); P = 0.0005], indicating heterogeneity ($I^2 = 94\%$). Additionally, there is no statistical difference between the RIRS and mini-PCNL groups [MD = -0.41; 95% CI (-0.35, 0.07); P = 0.19], with moderate heterogeneity ($I^2 = 25\%$). In addition, the publication is unbiased, which was assessed by Egger's test.

3.4.2.2. Analysis of operation time

Ten studies mentioned the operation time included 858 patients. According to the analysis, there was an enormous difference between the PCNL group and RIRS group [MD = -8.41; 95% CI (-9.94,-6.89); P < 0.00001] with high heterogeneity ($I^2 = 98\%$). There is no statistical difference between the RIRS group and the micro-PCNL group [MD = 0.17; 95% CI (-2.03, 2.37); P = 0.88], indicating high heterogeneity ($I^2 = 93\%$). Additionally, there is a statistical difference between the RIRS and mini-PCNL groups [MD = -16.34; 95% CI (-18.45,-14.23); P < 0.00001], with high heterogeneity ($I^2 = 99\%$). In addition, the publication is unbiased, which was assessed by Egger's test.

3.4.2.3. Analysis of the stone size

Nine studies mentioned the age included 836 patients. According to the analysis, there was an enormous difference between the PCNL group and RIRS group [MD = -1.33; 95% CI (-1.90, -0.76); P < 0.00001] with high heterogeneity ($I^2 = 83\%$). There was a significant difference between the RIRS group and the micro-PCNL group [MD = -1.11; 95% CI (-1.79, -0.42); P = 0.0001], with high heterogeneity ($I^2 = 91\%$). Additionally, there is a statistical difference between the RIRS and mini-PCNL groups [MD = -1.87; 95% CI (-2.93, -0.81); P = 0.0005], with moderate heterogeneity ($I^2 = 30\%$). In addition, the publication is unbiased, which was assessed by Egger's test.

3.4.2.3. Analysis of stone location

Five studies mentioned the stone location included 468 patients. There is a statistical difference between the RIRS group and the micro-PCNL group [OR = 1.05; 95% CI (0.70, 1.58); P = 0.70], with heterogeneity ($I^2 = 50\%$) (**Figure** 7). Additionally, there was no statistical difference between the RIRS and the mini-PCNL

			_					
	Cturks or Cultureum	RIRS	5 Total	PCN	L	Mainht	Odds Ratio	Odds Ratio
	2 20 4 micro DCNI	Events	Total	Events	Total	weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Ci
	2.30.1 micro-PCNL	26	20	24	27	4.200	0.04 0.46 4.041	
	Viang 2020 Pop 2017	20	30	24	27	4.270	0.01 [0.10, 4.01]	
	Jie 2020	19	23	21	20	4.470	0.90 [0.20, 4.13]	
	Jia 2020 Holipold 2024	10	20	33	30	13.0%	0.14 [0.03, 0.07]	
	Frainski 2021	32	30	13	10	3.770	0.62 [0.10, 4.01]	
	EISUZ 2021	32	40	27	20	6.0%	0.30 [0.11, 1.23]	
	Dugari 2020 Subtotal (05% CI)	20	20	32	39	0.2%	0.88 [0.24, 3.14]	
	Subtotal (95% CI)	1 4 4	100	150	175	43.470	0.50 [0.29, 0.66]	•
	Hotorogonoity: Chiž-	144 5 40 df-	5 /D -	0.073-18-				
	Toot for everall effect:	0.43, ul =	ວ (F = ທີ່ – ທີ່ໃ	0.377, FF 125	- 070			
	restion overall effect.	2 = 2.39 (,r = 0.0	12)				
	2.30.2 mini-PCNL							
	Zhang 2021	67	73	34	40	4.5%	1.97 [0.59, 6.57]	
	Saad 2015	15	21	21	22	7.3%	0.12 [0.01, 1.09]	
	Resorlu 2012	88	95	100	106	8.7%	0.75 [0.24, 2.33]	
	Pelit 2016	24	32	38	45	9.8%	0.55 [0.18, 1.72]	
	Jones 2020	47	55	39	40	8.2%	0.15 [0.02, 1.26]	
	Gamal 2016	20	21	20	21	1.2%	1.00 [0.06, 17.12]	
	Ersoz 2021	32	45	27	31	11.5%	0.36 [0.11, 1.25]	
	Bas 2016	31	36	36	45	5.5%	1.55 [0.47, 5.12]	-
	Subtotal (95% CI)		378		350	56.6%	0.65 [0.41, 1.03]	\bullet
	Total events	324		315				
	Heterogeneity: Chi ² =	10.44, df	= 7 (P :	= 0.16); l ²	= 33%			
	Test for overall effect:	Z=1.83 ((P = 0.0)7)				
	Total (95% CI)		564		523	100.0%	0.59 [0.41, 0.84]	•
	Total events	468	004	465	020		0.00 [0111, 0.04]	•
	Hotorogonoity: Chi2-	16 / 9 0 0 P	- 13/6	2 - 0 22V	IZ - 210	x.		+ + + +
	Taet for overall effect:	7 - 2 92		- 0.22), 103)	- 21	70		0.005 0.1 1 10 200
	Toet for eubarous diff	2 - 2.00 (foroncoe:	, −0.0 Chi≧-1	03) 048 df-	1 (P -	∩ ⊿Q\ I≊ –	- 0%	RIRS PCNL
	restion suburoup uni	iciences.	- m	0.40. ul =	- (r =	0.48). ["=	.0.0	
FIGURE 2								
Forest plot	of stone-free rate in t	the RIRS	aroun	and the		aroup		
i orest plot	or stone-nee rate in i	UIC IVINO	group		CIVE	group.		

		RIRS		E	CNI			Mean Difference	Mean Difference
Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed. 95% Cl	IV. Fixed, 95% Cl
1.1.1 mini-PCNL									
Bas 2016	8.39	4.72	36	5.62	4.5	45	0.8%	2.77 [0.74, 4.80]	
Ersoz 2021	8.1	5.3	45	8.09	5.5	31	0.5%	0.01 [-2.47, 2.49]	
Gamal 2016	9.2	2.5	21	9.2	2.5	21	1.4%	0.00 [-1.51, 1.51]	
Jones 2020	9.2	3.5	55	8.8	2.13	40	2.5%	0.40 [-0.74, 1.54]	-
Pelit 2016	3.65	1.95	32	3.71	1.89	45	4.2%	-0.06 [-0.93, 0.81]	-+-
Resorlu 2012	9.3	5.2	95	9.6	1.9	106	2.6%	-0.30 [-1.41, 0.81]	
Saad 2015	6.44	4.84	21	6.93	3.55	22	0.5%	-0.49 [-3.04, 2.06]	
Zhang 2021	3	0.675	73	3.2	0.55	40	60.7%	-0.20 [-0.43, 0.03]	.
Subtotal (95% CI)			378			350	73.3%	-0.14 [-0.35, 0.07]	•
Heterogeneity: Chi ² =	9.28, df	= 7 (P =	0.23);	l² = 259	6				
Test for overall effect:	Z=1.31	(P = 0.1	19)						
1.1.2 micro-PCNL									
Dogan 2020	6	3.63	25	3.08	3.29	39	1.0%	2.92 [1.16, 4.68]	
Ersoz 2021	8.1	5.3	45	8.09	5.5	31	0.5%	0.01 [-2.47, 2.49]	
Halinski 2021	9.6	3.78	38	8.2	3.36	15	0.7%	1.40 [-0.68, 3.48]	
Jia 2020	4.3	2.5	25	4.5	2.7	36	1.9%	-0.20 [-1.52, 1.12]	
Sen 2017	10.9	3	23	4	2.3	25	1.4%	6.90 [5.38, 8.42]	
Wang 2020	1.75	0.65	30	1.6	0.83	27	21.2%	0.15 [-0.24, 0.54]	÷.
Subtotal (95% CI)			186			173	26.7%	0.62 [0.27, 0.96]	•
Heterogeneity: Chi ² =	79.82, d	lf = 5 (P	< 0.000	001); I²:	= 94%				
l est for overall effect:	Z= 3.48	(P = 0.)	JUU5)						
Total (95% CI)			564			523	100.0%	0.06 [-0.12, 0.24]	+
Heterogeneity: Chi ² =	102.49,	df = 13	(P < 0.0	00001);	l² = 87	'%			
Test for overall effect:	Z = 0.68	(P = 0.)	50)						
Test for subaroup dif	ferences	: Chi² =	13.38.	df = 1 (f	° = 0.0	003), l ^a	= 92.5%		KING FONE

06





groups [OR = 1.45; 95% CI (1.07, 1.96); P = 0.81], with low heterogeneity ($I^2 = 71\%$) (Figure 6). In addition, the publication is unbiased, which was assessed by Egger's test.

3.4.3. Postoperative complications 3.4.3.1. Postoperative fever rate analysis

Six studies that mentioned postoperative fever (Clavien–Dindo grade I) included 441 patients. According to the analysis. There was no enormous difference between the RIRS group and PCNL group [OR = 0.96; 95% CI (0.53, 1.75); P = 0.91] with moderate

heterogeneity ($I^2 = 52\%$). After grouping the six studies based on the usage of the mini-PCNL or micro-PCNL, the group of mini-PCNL declined completely to 0%, while that of micro-PCNL only dropped to 10%. There was a tremendous difference in the two subgroups which had conducted the micro-PCNL between the RIRS group and PCNL group [OR = 4.86; 95% CI (1.28, 18.49); P = 0.02] with heterogeneity ($I^2 = 10\%$). In addition, there was no significant difference in the subgroup which had taken the mini-PCNL between the RIRS group and PCNL group [OR = 0.53; 95% CI (0.26, 1.10): P = 0.09] without heterogeneity

Study or Subgroup	Evente	Total	Evonte	Total	Mojaht	M H Eivod 05% CL	M H Eixed 05% Cl
A 46 4 mobile	Events	TULAI	Events	Total	weight	M-H, FIXEU, 95% CI	M-H, FIXEU, 95% CI
1.10.1 peivis	45	~~	47	40	20.20	0.64.10.04.4.001	
Jones 2020	15	55	17	40	20.3%	0.51 [0.21, 1.20]	
Resoriu 2012	29	95	36	105	33.7%	0.84 [0.46, 1.53]	
Subtotal (95% CI)		150		145	54.0%	0.72[0.44, 1.17]	
Total events	44		53				
Heterogeneity: Chi ² = 0).90, df=	1 (P =	0.34); I ² =	:0%			
Test for overall effect: Z	Z = 1.34 (I	P = 0.1	8)				
1.16.2 upper/middle po	ole						
Jones 2020	15	55	3	40	3.6%	4.63 [1.24, 17.27]	
Resorlu 2012	28	95	12	105	11.4%	3.24 [1.54, 6.83]	
Subtotal (95% CI)		150		145	15.0%	3.57 [1.87, 6.82]	
Total events	43		15				
Heterogeneity: Chi ² = 0).21, df=	1 (P =	0.64); l ² =	:0%			
Test for overall effect: Z	Z = 3.85 (P = 0.0	0001)				
1.16.3 low pole							
Jones 2020	21	55	13	40	13.2%	1.28 [0.54, 3.02]	
Resorlu 2012	29	95	19	105	17.8%	1.99 (1.03, 3.85)	—
Subtotal (95% CI)		150		145	31.0%	1.69 [1.00, 2.85]	◆
Total events	50		32			. / .	
Heterogeneity: Chi ² = 0).63. df=	1 (P =	0.43); I ² =	: 0%			
Test for overall effect: Z	Z = 1.96 (P = 0.0)5)				
Total (95% CI)		450		435	100.0%	1.45 [1.07, 1.96]	◆
Total events	137		100			. / .	
Heterogeneity: Chi ² = 1	7.28. df=	= 5 (P =	= 0.004):	$ ^2 = 719$	%		
Test for overall effect: 7	Z = 2.39 (P = 0.0	12)		-		0.01 0.1 1 10 100
Test for subgroup diffe	rences: (Chi ² = 1	, 15.76. df:	= 2 (P =	: 0.0004)	l ² = 87.3%	RIRS mini-PCNL
			. o o. ur ·		0.00047.	1 - 01.070	

rirs PCNL Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl 1.15.1 pelvis Dogan 2020 0.48 [0.17, 1.35] 9 25 39 23.2% 21 Jia 2020 25 25.4% 0.35 [0.12, 1.00] 11 25 36 Sen 2017 15 23 16 25 11.8% 1.05 [0.32, 3.45] Subtotal (95% CI) 73 100 60.4% 0.54 [0.29, 1.00] Total events 35 62 Heterogeneity: Chi² = 1.95, df = 2 (P = 0.38); l² = 0% Test for overall effect: Z = 1.97 (P = 0.05) 1.15.2 upper/middle pole Dogan 2020 6 25 4 39 5.3% 2.76 [0.69, 11.02] 9.56 [1.85, 49.46] Jia 2020 9 25 2 36 2.3% 25 1.13 [0.34, 3.77] Sen 2017 23 11.1% 8 8 Subtotal (95% CI) 73 100 18.6% 2.64 [1.24, 5.61] 23 Total events 14 Heterogeneity: Chi² = 4.27, df = 2 (P = 0.12); l² = 53% Test for overall effect: Z = 2.53 (P = 0.01) 1.15.3 low pole Dogan 2020 25 39 14.5% 1.19 [0.42, 3.35] 10 14 Jia 2020 2 25 2 36 3.3% 1.48 [0.19, 11.26] Sen 2017 0 23 1 25 3.1% 0.35 [0.01, 8.96] Subtotal (95% CI) 73 100 21.0% 1.11 [0.46, 2.67] 12 17 Total events Heterogeneity: Chi² = 0.58, df = 2 (P = 0.75); l² = 0% Test for overall effect: Z = 0.24 (P = 0.81) Total (95% CI) 219 300 100.0% 1.05 [0.70, 1.58] 70 93 Total events Heterogeneity: Chi² = 15.84, df = 8 (P = 0.04); l² = 50% 0.02 0.1 10 50 Test for overall effect: Z = 0.23 (P = 0.82) RIRS PCNL Test for subaroup differences: Chi² = 10.29, df = 2 (P = 0.006), I² = 80.6% FIGURE 7 Forest plot of stone location between the RIRS group and the micro-PCNL group.

Frontiers in Pediatrics

	RIRS	5	PCN	L		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.28.1 micro-PCNL							
Jia 2020	6	25	1	36	2.8%	11.05 [1.24, 98.70]	
Sen 2017	4	23	2	25	7.1%	2.42 [0.40, 14.69]	
Subtotal (95% CI)		48		61	9.9%	4.86 [1.28, 18.49]	
Total events	10		3				
Heterogeneity: Chi ² = 1	l.11, df=	1 (P =	0.29); l ² =	= 10%			
Test for overall effect: Z	Z = 2.32 ((P = 0.0	12)				
1.28.2 mini-PCNL							
Bas 2016	2	36	1	45	3.8%	2.59 [0.23, 29,75]	
Jones 2020	0	55	2	40	12.9%	0.14 [0.01, 2.97]	• • •
Saad 2015	2	21	4	22	15.9%	0.47 [0.08, 2.91]	
Zhang 2021	13	73	12	40	57.4%	0.51 [0.20, 1.25]	
Subtotal (95% CI)		185		147	90.1%	0.53 [0.26, 1.10]	
Total events	17		19				
Heterogeneity: Chi ² = 2	2.38, df =	3 (P =	0.50); l ² =	= 0%			
Test for overall effect: Z	Z = 1.70 ((P = 0.0	19)				
Total (95% CI)		233		208	100.0%	0.96 [0.53, 1.75]	+
Total events	27		22				
Heterogeneity: Chi ² = 1	10.49, df	= 5 (P =	= 0.06); l ^a	= 52%			
Test for overall effect: Z	Z = 0.12 (P = 0.9	1)				0.01 0.1 1 10 100
Test for subaroup diffe	rences:	Chi²=∺	8.10. df=	1 (P =	0.004), I ²	= 87.7%	RIRS PUNL
Test for subaroup diffe	rences:	Chi ² = 1	8.10. df=	1 (P =	0.004). I²	= 87.7%	



 $(I^2 = 0\%)$. In addition, the publication is unbiased, which was assessed by Egger's test.

3.4.3.2. Analysis of Clavien-Dindo complication

Nine studies mentioned Clavien-Dindo grade I included 784 patients. According to the analysis, there was a meaningful

difference between the PCNL group and RIRS group [OR = 0.48; 95% CI (0.31, 0.76); P = 0.002] with moderate heterogeneity ($I^2 = 30\%$). The Micro-PCNL group dropped to 12%, while the mini-PCNL group only dropped to 29%. There was no significant difference between the RIRS group and the micro-PCNL group [OR = 0.90; 95% CI (0.33, 2.43); P = 0.83], indicating low

heterogeneity ($I^2 = 12\%$). Additionally, the subgroups using mini-PCNL were significantly different between the RIRS and PCNL groups [OR = 0.41; 95% CI (0.24, 0.69); P = 0.0008], with moderate heterogeneity ($I^2 = 29\%$). In addition, the publication is unbiased, which was assessed by Egger's test (Figure 9).

Eight studies mentioned the Clavien–Dindo grade II included 711 patients. According to the analysis, there was no enormous difference between the RIRS group and PCNL group [OR = 0.66;95% CI (0.36, 1.23); P = 0.19] with moderate heterogeneity ($I^2 =$ 53%). The heterogeneity in the micro-PCNL group was completely fallen to 0%, with a certain difference between the RIRS and PCNL [OR = 3.73; 95% CI (1.02, 13.71); P = 0.05]. At the same time, mini-PCNL was performed in the other five papers, with significant differences between the RIRS and PCNL groups [OR = 0.32; 95% CI (0.14, 0.73); P = 0.007] and medium heterogeneity ($I^2 = 37\%$). In addition, the publication is unbiased, which was assessed by Egger's test (Figure 10).

Meta-analysis of Clavien–Dindo grade III between the RIRS group and PCNL group including 329 patients. The analysis concluded that there was no noticeable difference between the RIRS group and the PCNL group [OR = 1.71. 95% CI (0.65, 4.50); P = 0.28] with low heterogeneity ($I^2 = 21\%$). In two studies involving micro-PCNL manipulation, Jia's article, and Halinski's article, there was no obvious difference between the RIRS group and the PCNL group [OR = 2.73; 95% CI (0.69, 10.86); P = 0.15]. In addition, the heterogeneity of the micro-PCNL group increased to 21%, while that of the mini-PCNL group completely decreased to 0%, and there was no significant difference between the RIRS and PCNL groups [OR = 0.98; 95% CI (0.23, 4.14); P = 0.98]. In addition, the publication is unbiased, which was assessed by Egger's test (**Figure 11**).

3.4.3.3. Analysis of pooled postoperative complication rate Twelve studies mentioned the complication rate included 1,023 patients. According to the analysis, there was a meaningful difference between the PCNL group and RIRS group [OR = 0.67; 95% CI (0.46, 0.97); P = 0.03] with moderate heterogeneity ($I^2 =$ 12%). When twelve studies were grouped according to the use of mini-PCNL or micro-PCNL, heterogeneity decreased in both groups but to different degrees. There was no significant difference between the RIRS group and the micro-PCNL group [OR = 1.62; 95% CI (0.73, 3.60); P = 0.23], indicating heterogeneity ($I^2 = 0$ %). Additionally, the complication rate was significantly different between the RIRS and mini-PCNL groups [OR = 0.52; 95% CI (0.34, 0.79); P = 0.003], with low heterogeneity ($I^2 = 0$ %). In addition, the publication is unbiased, which was assessed by Egger's test.

4. Discussion

The first treatment choice for most pediatric kidney stones is ESWL (20). However, ESWL has numerous limitations, including the need for multiple sessions, general anesthesia requirements, and the shock waves' long-term effects on the developing kidney are unknown (21–23). Over the last few years, more minimally invasive surgeries have been frequently utilized as a substitute for the previous ESWL and open surgeries for kidney stones in children, such as PCNL and RIRS (24–26). Currently, the number of studies on the efficacy and prognosis of RIRS and PCNL is increasing; however, there is no agreement. Additionally, past meta-analyses that relied on a small number of earlier



~	RIRC	· · · ·	PUN	L 		Odds Ratio		Odds	s Ratio		
Study or Subgroup	Events	lotal	Events	lotal	weight	M-H, Fixed, 95% Cl		M-H, FiX	ed, 95% CI		
1.32.1 micro-PCNL											
Jia 2020	6	25	2	36	19.5%	5.37 [0.98, 29.27]			-		-
Halinski 2021	1	38	1	15	21.9%	0.38 [0.02, 6.47]					
Subtotal (95% CI)		63		51	41.4%	2.73 [0.69, 10.86]		-			
Total events	7		3								
Heterogeneity: Chi ² =	= 2.47, df =	: 1 (P =	0.12); l ² =	= 60%							
Test for overall effect	:Z=1.43	(P = 0.1	5)								
1.32.2 mini-PCNL											
Saad 2015	0	21	2	22	37.4%	0.19 (0.01, 4.22)	•	-	<u> </u>		
Pelit 2016	1	32	1	45	12.6%		-				
Jones 2020	2	55	n	40	8.6%	3 79 [0 18 81 02]					
Subtotal (95% CI)	-	108	Ť	107	58.6%	0.98 [0.23, 4,14]					
Total events	3		3								
Heterogeneity: Chi ² =	=1 89 df=	2 (P =	0.39) 17:	- 0%							
Test for overall effect	: Z = 0.02	(P = 0.9	38)	• ••							
Total (95% CI)		171		158	100.0%	1.71 [0.65, 4.50]					
Total events	10		6								
Heterogeneity: Chi ² =	= 5.04, df =	: 4 (P =	0.28); l² =	= 21%				1	1	10	100
Test for overall effect	:Z=1.08	(P = 0.2	28)				0.01 0	.I PIPS	PONI	10	100
Test for subaroup dif	fferences:	Chi²=	1.01. df=	1 (P =	0.32), I ² =	0.8%		RING	FUNE		



studies and research indicators were unable to make enough conclusions at once. So, we conducted a meta-analysis to compare the difference between RIRS and PCNL in terms of treatment means, treatment outcomes, age of patients, stone size, stone location, and postoperative complications, aiming to provide practical surgical guidance to patients.

Thirteen clinical trials were analyzed in our study, five of which were of high quality and eight of lower quality. Various

postoperative complications during kidney stone surgery become a major key factor in the choice of surgical approach. We compared the effects of multiple complications in RIRS and PCNL according to our results.

In Figure 2, our systematic review of 13 studies showed a tremendous difference in stone-free rate between the RIRS and PCNL groups. The reasons are as follows. First, PCNL usually requires multiple entrances, while RIRS always eliminates stones through a single entrance. PCNL is prone to remove large-size stones, staghorn kidney stones, and solitary kidney stones. Second, PCNL has a large dermorenal passage, fast water flow rate, and relatively high stone removal efficiency. In contrast, the low stone clearance rate of RIRS was attributed to its anatomical limitations in the treatment of stones (27). In terms of the anatomy of the kidney, such as the infundibulopelvic angle, the infundibular width, and the infundibular length make a hardship to remove the lower pole stones via RIRS (28). Besides, the insertion of the laser probe capable of reducing the deflection of the flexible is ureterorenoscopy and was not conducive for RIRS to treat the lower pole stones (27).

Before analyzing the data for the complication, it is comparably important to analyze key characteristic data (eg. the mean age, the operation time, the stone size, and stone location) shown in Figures 3-7. First, we found that the mean age of patients in the RIRS group was equal to that of mini-PCNL. Of note, the mean age of children in the micro-PCNL group was significantly younger than that in the RIRS group. This result indicated that micro-PCNL may be a better clinical option for younger children, which implied age could be a risk factor for postoperative adverse effects in different PCNLs. Simultaneously, there was no exact age recommendation concerning lithotripsy in EAU guideline on pediatric urology in 2022 (29). There will be room to explore the association between the age of children and PCNL in the future. Second, we found that the mean operation time in the RIRS group was shorter than that in the mini-PCNL group. Notably, the mean operation time in the micro-PCNL group was equal to that in the RIRS group. The previous study had documented a relationship between bleeding requiring transfusion and operation time (30). Consequently, micro-PCNL and RIRS can possibly decrease severe complications. Third, about stone size, we found that the average size of stones in the RIRS group was smaller than that in the PCNL group, and ranged from 7 mm to 21.06 mm, mostly 10 mm-20 mm. This result indicated that micro-PCNL may excel in eliminating 10 mm-20 mm kidney calculi. More further studies should concentrate on the exact association between the stone size and the effects of different PCNL due to the high heterogeneity of stone sizes in included studies. Forth, the pelvis stones were mostly eliminated by PCNL, and the stones in upper/middle pole calyces were mostly disposed of by RIRS. Compared with mini-PCNL, RIRS was more frequently conducted for the stones in lower pole calyces. Most included studies were published before 2022, so our results were not consistent with the latest recommendation of the European Association of Urology (29).

In **Figure 8**, we found that the occurrence of postoperative fever in the RIRS group was better than that of the mini-PCNL group, and the treatment effect of the RIRS group was worse than that of the micro-PCNL group. Notably, the articles with fever data carried out preoperative sterile urine culture for all patients. Except for Sen's article without mentioning further antibiotic treatment, the other articles entirely used antibiotic prophylaxis or antimicrobial spectrum for treatment. The reasons that led to this result may be the following. According to Kallidonis et al., the drawbacks of mini-PCNL techniques are increased intrarenal pressure and operative time (31). High pressure favors the occurrence of urinary tract infections, which in turn causes fever. What is more, compared with RIRS, mini-PCNL has been bound up with more significant complications such as postoperative bleeding and organic injury, due to its invasive skin puncture (32). Additionally, it is also possible that fluoroscopy-guided renal access increases the radiation exposure time and higher risk of iatrogenic visceral injury, thus making complications more lethal, supposing a larger size PCNL is conducted (32).

We summarized the Clavien-Dindo grade I, II, and III complication data for the combined analysis from the perspective of efficacy and safety, respectively, as shown in Figures 9-11. For Clavien-Dindo grade I, as is shown in Figure 9, the complication rate was lower in the RIRS group than in the mini and micro-PCNL groups. For Clavien-Dindo grade II in Figure 10, micro-PCNL had better therapeutic effects than the RIRS group. For Clavien-Dindo grade III in Figure 11, the difference in complication rates between the RIRS group and the PCNL group was not statistically significant. When it comes to pooled complication rate in Figure 12, the mini-PCNL had statistically better effects. Collectively, the micro-PCNL is possibly prone to a decline in the complication rate. The reasons for these results are complex, but it is important that RIRS clear kidney stones through natural pathways, while PCNL, especially the mini-PCNL, cleans the stones by establishing a large incision. Also, it is worth noting that there are at least half of the children are not capable to obtain retrograde process, who should be left stents to enlarge the orifice and receive a second session, thus possibly ascending the complication rate (33).

We find the following conclusions when we compare our research to other meta-analyses already done. First and foremost, Lu et al. suggested that PCNL therapy had a higher stone-free rate for pediatric patients. Nevertheless, they included only four studies for analysis which is not enough, and there was no statistical significance in complication rate and SFR (34). Zhao et al. concluded that more minimally invasive PCNL is the optimal procedure for managing kidney stones in children by contrasting the results of SWL, RIRS, and PCNL at different degrees of minimal invasiveness. This conclusion is essentially the same as in the meta-analysis by Sharma et al. on adult kidney stones. However, these two studies included fewer RCTs, and their findings need more high-quality RCTs for validation (35, 36). In the study by Gu et al., in contrast to micro-PCNL, RIRS had a higher SFR and more hemoglobin loss, and no differences were identified in hospitalization, fluoroscopy durations, or complication rates (37). However, in the study of Chen et al., compared with PCNL, without compromising the stone-free rate or the length of surgery, RIRS has a superior prognosis when treating pediatric patients with

upper urinary stones. Similarly, their experiments did not include enough RCTs. Moreover, Chen's study ignored the high heterogeneity of stone-free rate, operative time, hospital stay, and fluoroscopy time (38). In contrast, our study included sufficient RCTs and provided a more comprehensive and objective illustration of the problem.

There are several limitations to our study. First of all, only four included researches are of high quality via the jadad assessment, and some studies are retrospective, indicating that our study's authenticity and accuracy may be affected. Second, although thirteen studies were included, there were not a large amount of data being extracted. More parameters should be analyzed to determine children's superiority over RIRS or PCNL. Third, some uncontrolled factors may affect the outcomes, such as different races, different levels of surgical experience, and diet. Fourth, a significant limitation was the differences in mean stone size in our included studies, most of which are 10 mm-20 mm, while mean stone sizes are more extensive than 20 mm or more minor than 10 mm in some studies. Fifth, our study did not conduct subgroups to analyze the relationship between stone position, stone constituent, and efficacy of the surgeries. Ultimately, our meta-analysis does not find the absolute superiority of PCNL and RIRS in contemporary pediatric patient cohorts due to poor cases.

5. Conclusion

First and foremost, though the PCNL group had a significantly larger stone size, the mini and micro-PCNL had a higher stone-free rate than the RIRS group. Also, when performing micro-PCNL, the operation time was shorter than other surgery. Notably, considering the Dindo–Clavien classifications and overall complication rate, micro-PCNL tended to induce fewer postoperative complications. Collectively, we recommend micro-PCNL as a better therapeutic option for 10–20 mm pediatric kidney calculi.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

References

1. Matlaga BR, Schaeffer AJ, Novak TE, Trock BJ. Epidemiologic insights into pediatric kidney stone disease. *Urol Res.* (2010) 38(6):453-7. doi: 10.1007/s00240-010-0327-9

2. Novak TE, Lakshmanan Y, Trock BJ, Gearhart JP, Matlaga BR. Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. *Urology*. (2009) 74(1):104–7. doi: 10.1016/j.urology.2008.12.079

3. Ritchey M, Patterson DE, Kelalis PP, Segura JW. A case of pediatric ureteroscopic lasertripsy. J Urol. (1988) 139(6):1272-4. doi: 10.1016/S0022-5347 (17)42890-4

4. Bader MJ, Gratzke C, Seitz M, Sharma R, Stief CG, Desai M. The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. *Eur Urol.* (2011) 59(6):1054–9. doi: 10.1016/j. eururo.2011.03.026

Author contributions

Conception and design: YY, ZZ. Analysis and interpretation: YY, Y-nL, K-fL, Y-rH. Data collection: K-fL, Y-rH. Quality assessment: YY, Y-nL. Statistical analysis: YY, Y-nL, Y-rH. Writing the article: YY, Y-nL, K-fL, Y-rH, ZZ, Q-lW. Critical revision of the article: YY, Y-nL, K-fL, Y-rH, ZZ, Q-lW. Final approval of the article: YY, Y-nL, K-fL, Y-rH, ZZ, Q-lW. Overall responsibility: YY, ZZ. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Guangzhou Technology projects (No. 202102020744, No. 202102010244).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023. 1086345/full#supplementary-material.

5. Desai MR, Sharma R, Mishra S, Sabnis RB, Stief C, Bader M. Single-step percutaneous nephrolithotomy (microperc): the initial clinical report. J Urol. (2011) 186(1):140–5. doi: 10.1016/j.juro.2011.03.029

6. Higgins J, Thomas J. Cochrane handbook for systematic reviews of interventions (2022).

7. Bas O, Dede O, Aydogmus Y, Utangac M, Yikilmaz TN, Damar E, et al. Comparison of retrograde intrarenal surgery and micro-percutaneous nephrolithotomy in moderately sized pediatric kidney stones. *J Endourol.* (2016) 30 (7):765–70. doi: 10.1089/end.2016.0043

8. Dogan HS, Asci A, Kahraman O, Gasimov K, Bozaci AC, Tatanis V, et al. Comparison of efficiency and safety of retrograde intrarenal surgery and micropercutaneous nephrolithotomy in pediatric kidney stones smaller than 2 cm: a prospective cohort study. *J Endourol.* (2021) 35(8):1124–9. doi: 10.1089/end.2020.0624

9. Ersoz C, Ilktac A, Dogan B, Kalkan S, Danacioglu YO, Silay MS. The optimal settings of holmium YAG laser in treatment of pediatric urolithiasis. *Lasers Med Sci.* (2022) 37(1):317–21. doi: 10.1007/s10103-021-03251-y

10. Gamal SW, Ahmed M. 1133 Pediatric FURS vs PCNL for renal stones <2 cm: a randomized controlled study. *Eur Urol Suppl.* (2016) 15(3):e1133.

 Halinski A, Steyaert H, Wojciech M, Sobolewski B, Haliński A. Endourology methods in pediatric population for kidney stones located in lower calyx: FlexURS vs. Micro PCNL (MicroPERC[®]). Front Pediatr. (2021) 9:640995. doi: 10.3389/fped. 2021.640995

12. Jia H, Li J, Liu B, Zhang P, Yusufu A, Nan Y, et al. Comparison of super-mini-PCNL and flexible ureteroscopy for the management of upper urinary tract calculus (1 cm-2 cm) in children. *World J Urol.* (2021) 39(1):195–200. doi: 10.1007/s00345-020-03150-x

13. Jones P, Mishra D, Agrawal M, Griffin S, Somani BK. Outcomes of ureteroscopy vs mini-percutaneous nephrolithotomy for pediatric upper urinary tract calculi: comparative nonrandomized outcomes from two tertiary endourology referral centers. *J Endourol.* (2020) 34(7):735–8. doi: 10.1089/end.2020.0172

14. Pelit ES, Atis G, Kati B, Akin Y, Ciftci H, Culpan M, et al. Comparison of minipercutaneous nephrolithotomy and retrograde intrarenal surgery in preschool-aged children. *Urology.* (2017) 101:21–5. doi: 10.1016/j.urology.2016.10.039

15. Resorlu B, Unsal A, Tepeler A, Atis G, Tokatli Z, Oztuna D, et al. Comparison of retrograde intrarenal surgery and mini-percutaneous nephrolithotomy in children with moderate-size kidney stones: results of multi-institutional analysis. *Urology.* (2012) 80(3):519–23. doi: 10.1016/j.urology.2012.04.018

16. Saad KS, Youssif ME, Hamdy SAIN, Fahmy A, Hanno AGED, El-Nahas AR. Percutaneous nephrolithotomy vs retrograde intrarenal surgery for large renal stones in pediatric patients: a randomized controlled trial. *J Urol.* (2015) 194 (6):1716–20. doi: 10.1016/j.juro.2015.06.101

17. Sen H, Seckiner I, Bayrak O, Dogan K, Erturhan S. A comparison of micro-PERC and retrograde intrarenal surgery results in pediatric patients with renal stones. *J Pediatr Urol.* (2017) 13(6):619.e1-.e5. doi: 10.1016/j. jpurol.2017.04.022

18. Wang W, Li J, Ning C. Comparing micro-percutaneous nephrolithotomy and retrograde intrarenal surgery in treating 1 cm-2 cm solitary renal stones in pediatric patients aged less than 3 years. *J Pediatr Urol.* (2020) 16:S49–S50. doi: 10.1016/j. jpurol.2020.05.114

19. Zhang Y, Li J, Jiao JW, Tian Y. Comparative outcomes of flexible ureteroscopy and mini-percutaneous nephrolithotomy for pediatric kidney stones larger than 2 cm. *Int J Urol.* (2021) 28(6):650–5. doi: 10.1111/iju.14532

20. Riedmiller H, Androulakakis P, Beurton D, Kocvara R Gerharz E. EAU Guidelines on Paediatric Urology. *Eur Urol.* (2001) 40(5):589–99. doi: 10.1159/000049841

21. Krambeck AE, Gettman MT, Rohlinger AL, Lohse CM, Patterson DE, Segura JW. Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol.* (2006) 175 (5):1742–7. doi: 10.1016/S0022-5347(05)00989-4

22. Vlajković M, Slavković A, Radovanović M, Sirić Z, Stefanović V, Perović S. Longterm functional outcome of kidneys in children with urolithiasis after ESWL treatment. *Eur J Pediatr Surg*. (2002) 12(2):118–23. doi: 10.1055/s-2002-30167

23. Willis LR, Evan AP, Connors BA, Blomgren P, Fineberg NS, Lingeman JE. Relationship between kidney size, renal injury, and renal impairment induced by shock wave lithotripsy. J Am Soc Nephrol. (1999) 10(8):1753–62. doi: 10.1681/ASN.V1081753

24. Al Busaidy SS, Kurukkal SN, Al Hooti QM, Alsaraf MS, Al Mamari SA, Al Saeedi AK. Is RIRS emerging as the preferred option for the management of 2 cm-4 cm renal stones: our experience. *Can J Urol.* (2016) 23(4):8364–7. PMID: 27544560

25. Palmero JL, Durán-Rivera AJ, Miralles J, Pastor JC, Benedicto A. Comparative study for the efficacy and safety of percutaneous nefhrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) for the treatment of 2 cm-3 cm, 5 cm kidney stones. *Arch Esp Urol.* (2016) 69(2):67–72. PMID: 26959965

26. Zhao Z, Tuerxu A, Liu Y, Wu W, Simayi A, Zhong W, et al. Super-mini PCNL (SMP): material, indications, technique, advantages and results. *Arch Esp Urol.* (2017) 70(1):211–6. PMID: 28221155

27. Kilicarslan H, Kaynak Y, Kordan Y, Kaygisiz O, Coskun B, Gunseren KO, et al. Unfavorable anatomical factors influencing the success of retrograde intrarenal surgery for lower pole renal calculi. *Urol J.* (2015) 12(2):2065–8. doi: 10.1097/MOU. 00000000000059

28. Inoue T, Murota T, Okada S, Hamamoto S, Muguruma K, Kinoshita H, et al. Influence of pelvicaliceal anatomy on stone clearance after flexible ureteroscopy and holmium Laser lithotripsy for large renal stones. *J Endourol.* (2015) 29(9):998–1005. doi: 10.1089/end.2015.0071

29. <EAU-Guidelines-on-Paediatric-Urology-2022.pdf>.

30. Onal B, Dogan HS, Satar N, Bilen CY, Güneş A, Ozden E, et al. Factors affecting complication rates of percutaneous nephrolithotomy in children: results of a multiinstitutional retrospective analysis by the Turkish pediatric urology society. *J Urol.* (2014) 191(3):777–82. doi: 10.1016/j.juro.2013.09.061

31. Kallidonis P, Tsaturyan A, Lattarulo M, Liatsikos E. Minimally invasive percutaneous nephrolithotomy (PCNL): techniques and outcomes. *Turk J Urol.* (2020) 46(Supp. 1):S58–S63. doi: 10.5152/tud.2020.20161

32. Rice P, Somani BK. Percutaneous laser nephrolithotripsy: is it here to stay? Results of a systematic review. *Curr Opin Urol.* (2022) 32(2):185–91. doi: 10.1097/MOU.00000000000959

33. Corcoran AT, Smaldone MC, Mally D, Ost MC, Bellinger MF, Schneck FX, et al. When is prior ureteral stent placement necessary to access the upper urinary tract in prepubertal children? *J Urol.* (2008) 180(4 Suppl):1861–3; discussion 3–4. doi: 10. 1016/j.juro.2008.03.106

34. Lu P, Song R, Yu Y, Yang J, Qi K, Tao R, et al. Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: a PRISMA-compliant article. *Medicine*. (2017) 96(43):e8346. doi: 10.1097/MD. 00000000008346

35. Sharma G, Pareek T, Tyagi S, Kaundal P, Yadav AK, Thummala Y, et al. Comparison of efficacy and safety of various management options for large upper ureteric stones a systematic review and network meta-analysis. *Sci Rep.* (2021) 11 (1):11811. doi: 10.1038/s41598-021-91364-3

36. Zhao FZ, Li J, Tang L, Li CM, Zhang Y, Wang WY, et al. Comparison of efficacy and safety of minimally invasive procedures for 10–20 mm pediatric renal stones-a bayesian network meta-analysis. *J Pediatr Urol.* (2020) 16(6):771–81. doi: 10.1016/j. jpurol.2020.08.019

37. Gu Z, Yang Y, Ding R, Wang M, Pu J, Chen J. Comparison of retrograde intrarenal surgery and micro-percutaneous nephrolithotomy for kidney stones: a meta-analysis. *Urol Int.* (2021) 105(1-2):64-70. doi: 10.1159/000506716

38. Chen Y, Deng T, Duan X, Zhu W, Zeng G. Percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric patients with upper urinary stones: a systematic review and meta-analysis. *Urolithiasis*. (2019) 47(2):189–99. doi: 10. 1007/s00240-018-1039-9